PF-04995274

PF-04995274 is notable as the molecule that carried the pro-cognitive 5-HT4 hypothesis from rodents into clinically depressed patients. It is a selective 5-HT4 partial agonist designed for central activity, and it has been the centrepiece of the Oxford-led RESTAND experimental medicine studies in unmedicated major depressive disorder.

In a double-blind, placebo-controlled trial, ninety participants with major depressive disorder received seven days of PF-04995274, the selective serotonin reuptake inhibitor citalopram, or placebo, with emotional processing measured behaviourally and by functional magnetic resonance imaging ^[1]. Citalopram produced the expected antidepressant signature of reduced negative bias and lowered amygdala response, whereas PF-04995274 did not shift negative bias and instead increased medial frontal cortical activation across emotional valences; both active treatments were associated with early reductions in observer-rated depression relative to placebo, and PF-04995274 additionally reduced self-reported depression, state anxiety, and negative affect ^[1]. This dissociation suggests 5-HT4 agonism may drive antidepressant benefit through a mechanism distinct from monoamine reuptake inhibition.

A companion RESTAND report used a memory-encoding functional magnetic resonance imaging task in unmedicated depressed patients and found that six to nine days of PF-04995274 significantly increased hippocampal activity to novel versus familiar images, particularly on the left, together with greater left inferior parietal activation, while producing only limited change on behavioural memory measures ^[2]. These human imaging findings replicate and extend earlier work with the 5-HT4 agonist prucalopride, which improved verbal learning and memory in healthy volunteers, and they are consistent with the established role of the 5-HT4 receptor in hippocampal neuroplasticity ^[3].

In the RESTAND studies, PF-04995274 was administered at 15 mg once daily for roughly one week and was generally well tolerated in unmedicated depressed adults, though these were short experimental medicine studies rather than large safety trials. Long-term tolerability, drug-interaction behaviour, and cardiac safety across broad populations have not been established. As a selective, next-generation 5-HT4 agonist it was engineered to avoid the off-target cardiac liabilities of older non-selective agents, but comprehensive clinical safety characterization is still lacking.

PF-04995274 originated in Pfizer's central nervous system discovery efforts as a selective 5-HT4 partial agonist. After the compound became available for investigator-led research, academic groups at Oxford adopted it to test whether the robust pro-cognitive and antidepressant-like 5-HT4 effects seen in animals could be demonstrated in humans. The RESTAND experimental medicine programme, reported in 2026, provided the first clinical-population evidence that a selective 5-HT4 agonist modulates emotional and memory circuitry in depression, reinvigorating interest in the receptor as a psychiatric target.

Among translational psychiatrists PF-04995274 is viewed as the compound that revived the 5-HT4 antidepressant and pro-cognitive hypothesis, and its RESTAND results are frequently cited as support for developing 5-HT4 agonists for cognitive symptoms of depression. In nootropic circles it is discussed with cautious interest as one of the few centrally selective 5-HT4 agonists to reach human study, though it is not commercially available. Its standing derives from high-quality human imaging data rather than from any approved indication.